Remdesivir
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1992/2023-SML | 18. 10. 2023 | Gilead Sciences s.r.o. | 29 841 433,60 | 27 128 576,00 | 29 841 433,60 | 27 128 576,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Remdesivir_EP.pdf | Písemná zpráva zadavatele | 23. 10. 2023 06:44 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 29 841 433,60 | 27 128 576,00 | CZK |
Price Actually Paid in Each Year of Performance
| 1992/2023-SML | 2023 | 746 035,84 | 678 214,40 |